INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following:

	December 31,
	2016			2015
Intangible assets:
Finite-lived intangible assets	$	305,122		$	129,572
Indefinite-lived intangible assets		332,199			607,548
Gross intangible assets:		637,321			737,120
Less: Accumulated amortization		(83,541	)		(53,124	)
Net carrying value	$	553,780		$	683,996

Schedule of Net-Book-Value and Estimated Remaining Life of Finite-Lived Intangible Assets

The following table summarizes the net-book-value and estimated remaining life of the Company’s finite-lived intangible assets as of December 31, 2016:

	Net Balance at December 31, 2016		Average Remaining Life
Repurchased royalty rights	$	46,688	6.9 years
Acquired intellectual property		172,256	8.1 years
License payments for marketing approvals		1,869	4.9 years
SRCC in-place and above market tenant leases		768	Remaining lease terms
Total	$	221,581

Schedule of Future Amortization Expense of Finite-Lived Intangible Assets

As of December 31, 2016, the estimated future amortization expense associated with the Company’s finite-lived intangible assets for each of the five succeeding fiscal years is as follows:

Fiscal Year	Amount
2017	$	30,430
2018		30,400
2019		30,086
2020		27,605
2021		26,681
Thereafter		76,379
	$	221,581

Schedule of Indefinite-Lived Intangible Assets

Indefinite-lived intangible assets consisted of the following:

	December 31,
	2016		2015
In-Process Research and Development:
Pegvaliase	$	326,359	$	—
Kyndrisa		—		533,064
Other exons acquired with Prosensa		—		41,044
Reveglucosidase alfa		—		25,010
Other acquired pre-clinical compounds		5,840		8,430
Net carrying value	$	332,199	$	607,548